If Kevin and Stephanie Ness collect their $15 million asking price for the home on Sunset Blvd., it will be the second time ...

The goal is to introduce Biorizon Biotech's advanced biostimulation and biocontrol products into the Indian market.

Despite a strong Q2, Merck's stock fell due to concerns over Gardasil and Winrevair. See more on MRK stock and its ...

Research suggests that a compound in pomegranates may rejuvenate our cells, boosting immunity and muscles. Food and cosmetic ...

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Two more top editors at the Los Angeles Times resigned after Patrick Soon-Shiong stopped the publication’s expected endorsement of Vice President Kamala Harris.

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Bank of America analysts said prior to Thursday’s readout that Tyra Biosciences’ TYRA-300 could rival Johnson & Johnson’s ...

Lyell Immunopharma, Inc.'s strong financials, innovative CAR T-cell therapies, and strategic acquisitions position it for ...

Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an ...

Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...

GenSight Biologics is weeks away from running out of money. Again. | GenSight Biologics is weeks away from running out of ...